On January 30, 2023 GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, reported the half-year report of the liquidity contract with Crédit Industriel et Commercial (Press release, Genfit, JAN 30, 2023, https://ir.genfit.com/news-releases/news-release-details/genfit-half-year-report-liquidity-contract-credit-industriel-5 [SID1234626642]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of December 31, 2022:

138,691 shares
€534 070.18
During the second half of 2022, total trading was:

On the buy side: 1339,376 shares for a total amount of €5,332,876.57
On the sell side: 1360,706 shares for a total amount of €5,417,420.02
During this same period, the number of trades were:

On the buy side: 2,627
On the sell side: 2,681
As a reminder, upon signing of the contract, the following resources appeared on the liquidity account:

27, 911 shares
€769 849,43